GlassScriptPhysician profile
Fawaz Al-Ejel
NPI 1871567651
$7,829.73
in general payments reported to CMS, 2019-2025
29 companies · $1,666 in 2025
The $1,666 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $851 · 2021: $979 · 2022: $1,010 · 2023: $898 · 2024: $1,718 · 2025: $1,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,971 · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,970.93 |
| Education | $309.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $822.16 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $697.64 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $637.08 | 2019-2025 | Ultomiris, Soliris |
| Amgen INC. | $596.47 | 2019-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $550.26 | 2019-2023 | Korsuva, Veltassa |
| Otsuka America Pharmaceutical, INC. | $518.27 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $500.23 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $436.59 | 2021-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $378.92 | 2020-2024 | Acthar, Terlivaz |
| Ardelyx, INC. | $322.18 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Fresenius USA Marketing, INC. | $285.98 | 2019-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $270.79 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $266.51 | 2019-2025 | Vafseo, Auryxia |
| Opko Pharmaceuticals, LLC | $256.00 | 2019-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.79 | 2023-2025 | Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $201.24 | 2023-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $193.03 | 2023-2025 | |
| Glaxosmithkline, LLC. | $175.81 | 2020-2025 | Jesduvroq, Benlysta |
| Novo Nordisk INC | $117.91 | 2025 | Wegovy |
| Horizon Therapeutics Plc | $73.48 | 2019-2023 | Krystexxa |
| Genzyme Corporation | $65.35 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.64 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $40.79 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $30.63 | 2021 | |
| Shield Therapeutics INC | $30.22 | 2024 | |
| Xeris Pharmaceuticals, INC. | $23.01 | 2024 | Keveyis |
| Apellis Pharmaceuticals, INC. | $21.11 | 2025 | Empaveli |
| Daiichi Sankyo INC. | $20.60 | 2023 | Injectafer |
| Scpharmaceuticals INC. | $20.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fawaz Al-Ejel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.